Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like ...
Continue reading to learn more about mazdutide compared to tirzepatide and what you should know about each. Mazdutide is not ...
Medications aren't lifelong contracts. You can switch from one to another — if it's safe for you to do so and under the guidance of a healthcare provider, of course. So, if you're taking tirzepatide ...
Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...
To conduct a systematic review and meta-analysis comparing tirzepatide versus placebo for weight management, with analyses stratified by diabetes status to precisely assess its efficacy and safety in ...
INDIANAPOLIS, Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity ...
Adults taking tirzepatide injection in a clinical trial lost on average 21.8 kg (48 lbs.) at the highest dose TORONTO, July 9, 2025 /CNW/ - Eli Lilly Canada is pleased to announce that ZEPBOUND™ ...
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results